[Next generation zebrafish-based drug discovery and precision medicine]

Area of Science:

• Drug Discovery and Development
• Genomics and Personalized Medicine
• Zebrafish Models in Research

Background:

• Developing first-in-class drugs for intractable diseases remains a significant challenge in 21st-century medicine.
• Phenotypic screening is a historically successful method, contributing to 62% of FDA-approved first-in-class drugs.
• Traditional drug discovery often struggles to address unmet medical needs effectively.

Purpose of the Study:

• To highlight the impact of next-generation zebrafish drug discovery for high-throughput phenotypic screening.
• To explore the potential of zebrafish as an individualized medical and diagnostic tool.
• To introduce phenomics-based personalized medicine using patient-derived cancer xenograft zebrafish.

Main Methods:

• Utilizing high-throughput quantitative live in vivo phenotypic screening with zebrafish.
• Employing patient-derived cancer xenotransplantation in zebrafish models.
• Integrating phenomics data with conventional omics platforms for individualized medicine.

Main Results:

• Zebrafish drug discovery enables efficient and rapid phenotypic screening.
• Zebrafish models demonstrate high efficiency and speed in engrafting patient-derived cancer xenografts.
• This approach is poised to become a valuable clinical ex vivo diagnostic system.

Conclusions:

• Next-generation zebrafish drug discovery is transforming global strategies for identifying novel therapeutics.
• Zebrafish xenografts offer a promising platform for phenomics-based personalized medicine.
• This represents a paradigm shift towards true next-generation precision medicine for drug selection and dosage.